-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Sarepta Therapeutics with Outperform Rating, Announces Price Target of $32

Benzinga·12/09/2025 13:15:06
Listen to the news
Wedbush analyst Yun Zhong initiates coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform rating and announces Price Target of $32.